Nexentis Technologies Inc. Common Stock (NXTS)
Stock · NASDAQ · Industrials
$0.645as of 10/16/2026
Price chart
NXTS Signal Track Record
How signals performed across all stocks →What NXTS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 21 | -9.6% | 29% | October 7, 2026 |
| Bollinger Band Breakout | 15 | -29.5% | 7% | June 22, 2026 |
| Volume Spike | 15 | -32.4% | 20% | September 24, 2026 |
| Any 20-session window (baseline) | -15.2% | 21% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NXTS
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all m…
- Sector
- Industrials
- Industry
- Agricultural Chemicals
- Employees
- 7
- Website
- www.n2off.com/
Fundamentals
- 1-day range
- $0.5994$0.6872
- Market cap
- $2.80M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-55.49
- Dividend yield
- —
- Beta
- 1.93
- Avg. volume
- 353.4K
How Nexentis Technologies Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 31, 2025 · via SEC EDGAR / Finnhub
Nexentis Technologies Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NXTSNexentis Technologies Inc. Common Stock$0.645▼ 5.43%Market cap $2.80MP/E —$0.6$32.9
- SNESSenesTech Inc. Common Stock$0.647▼ 7.44%Market cap $6.74MP/E —$0.6101$4.19
- EVGNEvogene Ltd Ordinary Shares$0.39▼ 2.50%Market cap $9.08MP/E —$0.3521$1.49
- FRTTFort Technology Inc. Common Shares$0.54▼ 10.00%Market cap $14.75MP/E —$0.6003$4.09
- BIOXBioceres Crop Solutions Corp. Ordinary Shares$0.276▼ 6.12%Market cap $22.76MP/E —$0.28$2.19
- AVDAmerican Vanguard Corporation Common Stock ($0.10 Par Value)$1.06▼ 15.20%Market cap $88.01MP/E —$1.13$5.55
- CBUSCibus Inc. Class A Common Stock$1.32▲ 2.33%Market cap $142.74MP/E —$1.09$4.19
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NXTS Nexentis Technologies Inc. Common Stock | $2.80M | — | $0.645 | ▼ 5.43% | $0.6$32.9 |
| SNES SenesTech Inc. Common Stock | $6.74M | — | $0.647 | ▼ 7.44% | $0.6101$4.19 |
| EVGN Evogene Ltd Ordinary Shares | $9.08M | — | $0.39 | ▼ 2.50% | $0.3521$1.49 |
| FRTT Fort Technology Inc. Common Shares | $14.75M | — | $0.54 | ▼ 10.00% | $0.6003$4.09 |
| BIOX Bioceres Crop Solutions Corp. Ordinary Shares | $22.76M | — | $0.276 | ▼ 6.12% | $0.28$2.19 |
| AVD American Vanguard Corporation Common Stock ($0.10 Par Value) | $88.01M | — | $1.06 | ▼ 15.20% | $1.13$5.55 |
| CBUS Cibus Inc. Class A Common Stock | $142.74M | — | $1.32 | ▲ 2.33% | $1.09$4.19 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Nexentis’ MitoCareX Announces Expansion Of Drug Discovery Platform Into Disease Pathway Analysis, Adds Bioinformatician To Teambenzinga · 10/12/2026
- Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google CloudYahoo · 10/7/2026
- Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google CloudYahoo · 10/7/2026
- Nexentis Technologies Unit MitoCareX Bio Launches Its Computational Drug Discovery Infrastructure On Google Cloud PlatformBenzinga · 10/7/2026
- Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory BoardYahoo · 9/24/2026
- Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug DiscoveryYahoo · 9/23/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 58
- Total value held
- $38
- Institutional holders
- 1
- Unknown58
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
NXTS Unit MitoCareX Bio Launches Cloud‑Based Drug Discovery Platform
MitoCareX Bio, a unit of Nexentis Technologies, has deployed its computational drug discovery infrastructure on the Google Cloud Platform. The deployment is intended to improve the speed and scalability of its biotech research services. This development comes as the stock is trading near its recent support level after a period of low momentum.
NXTS Unit MitoCareX Bio Launches Cloud‑Based Drug Discovery Platform. MitoCareX Bio, a unit of Nexentis Technologies, has deployed its computational drug discovery infrastructure on the Google Cloud Platform. The deployment is intended to improve the speed and scalability of its biotech research services. This development comes as the stock is trading near its recent support level after a period of low momentum.